135 related articles for article (PubMed ID: 7840053)
1. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group.
Sueta CA; Gheorghiade M; Adams KF; Bourge RC; Murali S; Uretsky BF; Pritzker MR; McGoon MD; Butman SM; Grossman SH
Am J Cardiol; 1995 Jan; 75(3):34A-43A. PubMed ID: 7840053
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).
Califf RM; Adams KF; McKenna WJ; Gheorghiade M; Uretsky BF; McNulty SE; Darius H; Schulman K; Zannad F; Handberg-Thurmond E; Harrell FE; Wheeler W; Soler-Soler J; Swedberg K
Am Heart J; 1997 Jul; 134(1):44-54. PubMed ID: 9266782
[TBL] [Abstract][Full Text] [Related]
3. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine.
Stanek B; Sturm B; Frey B; Hülsmann M; Bojic A; Berger R; Rödler S; Locker G; Grimm M; Laufer G; Pacher R
J Heart Lung Transplant; 1999 Apr; 18(4):358-66. PubMed ID: 10226901
[TBL] [Abstract][Full Text] [Related]
4. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
[TBL] [Abstract][Full Text] [Related]
5. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.
Rubin LJ; Mendoza J; Hood M; McGoon M; Barst R; Williams WB; Diehl JH; Crow J; Long W
Ann Intern Med; 1990 Apr; 112(7):485-91. PubMed ID: 2107780
[TBL] [Abstract][Full Text] [Related]
6. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
Barst RJ; Rubin LJ; McGoon MD; Caldwell EJ; Long WA; Levy PS
Ann Intern Med; 1994 Sep; 121(6):409-15. PubMed ID: 8053614
[TBL] [Abstract][Full Text] [Related]
7. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
[TBL] [Abstract][Full Text] [Related]
8. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E1--bridge to cardiac transplantation. Technique, dosage, results.
Pacher R; Stanek B; Hülsmann M; Berger R; Siegel A; Daneschvar H; Rödler S; Frey B; Grimm M; Laufer G
Eur Heart J; 1997 Feb; 18(2):318-29. PubMed ID: 9043849
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R
J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
[TBL] [Abstract][Full Text] [Related]
11. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.
Humbert M; Sanchez O; Fartoukh M; Jagot JL; Le Gall C; Sitbon O; Parent F; Simonneau G
Eur Respir J; 1999 Jun; 13(6):1351-6. PubMed ID: 10445611
[TBL] [Abstract][Full Text] [Related]
12. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial.
Oliva F; Latini R; Politi A; Staszewsky L; Maggioni AP; Nicolis E; Mauri F
Am Heart J; 1999 Aug; 138(2 Pt 1):247-53. PubMed ID: 10426835
[TBL] [Abstract][Full Text] [Related]
13. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
[TBL] [Abstract][Full Text] [Related]
14. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study.
Gollub SB; Elkayam U; Young JB; Miller LW; Haffey KA
J Am Coll Cardiol; 1991 Aug; 18(2):383-90. PubMed ID: 1677368
[TBL] [Abstract][Full Text] [Related]
16. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
Sitbon O; Delcroix M; Bergot E; Boonstra AB; Granton J; Langleben D; Subías PE; Galiè N; Pfister T; Lemarié JC; Simonneau G
Am Heart J; 2014 Feb; 167(2):210-7. PubMed ID: 24439982
[TBL] [Abstract][Full Text] [Related]
17. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
[TBL] [Abstract][Full Text] [Related]
18. Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure.
Patterson JH; Adams KF; Gheorghiade M; Bourge RC; Sueta CA; Clarke SW; Jankowski JP; Shaffer CL; McKinnis RA
Am J Cardiol; 1995 Jan; 75(3):26A-33A. PubMed ID: 7840051
[TBL] [Abstract][Full Text] [Related]
19. Effect of prostacyclin and prazosin in the treatment of congestive heart failure; with special reference to the sympathetic nervous system.
Yui Y; Sakurai T; Nakajima H; Kawai C
Jpn Circ J; 1984 Apr; 48(4):365-72. PubMed ID: 6371282
[TBL] [Abstract][Full Text] [Related]
20. Beneficial hemodynamic effects of prostaglandin E1 infusion in catecholamine-dependent heart failure: results of a prospective, randomized, controlled study.
Pacher R; Globits S; Wutte M; Rödler S; Heinz G; Kreiner G; Radosztics S; Berger R; Presch I; Weber H
Crit Care Med; 1994 Jul; 22(7):1084-90. PubMed ID: 8026195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
